top of page

Inflection Biosciences Announces Pre-clinical Data to be Presented at 2nd EACR-AACR-SIC Special Conf

Dublin, Ireland, June 23, 2017 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that data on IBL-301, a pan-PIM/pan-PI3K/mTOR inhibitor, will be presented at the 2nd EACR-AACR-SIC Special Conference 2017 being held in Florence, Italy on June 24 - 27, 2017.

The pre-clinical data was generated through a collaboration between Inflection Biosciences and Trinity College Dublin, led by Dr. Kathy Gately, Clinical Lecturer Thoracic Oncology Research at the Trinity Translational Medicine Institute, St. James’s Hospital Dublin. The collaboration is jointly funded by Enterprise Ireland and Inflection Biosciences Ltd.

Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences commented “This work has shown for the first time that PIM kinase is a key regulator of resistance to PI3K/mTOR inhibition in NSCLC. The data provides further rationale for the company’s strategy of co-targeting PIM kinase and PI3K/mTOR pathways.”

The details for the poster presentations are as follows:

Poster Title: Pim kinase: A mechanism of resistance to PI3K-mTOR inhibition in NSCLC

Date & Time: 10.15 am – 17.00 pm, Monday 26th June, 2017

Presenter: Dr. Kathy Gately

ID Number: 383

Session Track: Experimental/Molecular Therapeutics, Pharmacogenesis II

Location: Poster Area, Exhibition Hall, Firenze Fiera

The full abstract can be viewed here.

About PIM/PI3 kinase inhibitors

The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signalling pathways. PIM kinase, which produces parallel oncogenic signals to AKT and mTOR and shares several downstream molecular targets, is increasingly recognised as a major compensatory signalling pathway. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit


bottom of page